Shares of Amylyx Pharmaceuticals Inc. (AMLX) touched a new 52-week high of $17.20 yesterday, and that represents a gain of over 50% in less than a month.
Shares of Arcutis Biotherapeutics Inc. (ARQT) have nearly doubled in value over the past year, thanks to the success of its flagship product ZORYVE. Since its launch in August 2022, ZORYVE has demonstrated strong and accelerating commercial momentum. Is ZORYVE the only product that Arcutis is focusing on?
Shares of Greenwich LifeSciences Inc. (GLSI) have been on a tear over the past ten days as the clinical-stage biotech pushes ahead with its financing strategy and prepares to implement risk-reducing modifications to the phase III trial of its investigational breast cancer immunotherapy, GLSI-100, upon the regulatory go-ahead.
For Climb Bio Inc. (CLYM), 2026 promises to be a data-rich year, with study results from two of its core programs poised to shape the company's strategy and guide subsequent development phases.
January 30, 2026 15:51 ET The Federal Reserve policy decision was the main event in the final week of January, which saw a heavy flow of economics news. Several data reflecting the trends in the U.S. economy were also released during the week. The interest rate decision from Canada also was in focus. In Europe, economic sentiment data gained attention. The policy decision from Singapore was the highlight in Asia.